NY-AQARA
Aqara, a leading provider of smart home products, announced the global availability of its next-generation Matter hub, the Hub M3. Designed with a focus on edge computing, the M3 prioritizes privacy and local automation capabilities that can operate independently of internet connection or even the hub itself1. Thanks to the versatile connectivity built-in, it seamlessly integrates Aqara accessories, infrared-compatible gadgets and a number of third-party Matter devices, making it a central point for smart home automation while ensuring privacy and easy setup.
“Aqara is committed to creating the ultimate smart home experience that continuously adapts to users’ evolving needs,” said Cathy You, Aqara Senior Vice President of Global Business and Strategy. “The Hub M3's edge computing capabilities will provide users with an added layer of stability and safety, while its Matter compatibility will significantly enhance interoperability and choice for users."
Debuted at CES in January, the M3 stands out as an Edge Hub by enabling not only data privacy through end-to-end encrypted, local storage but also advanced, local automation capabilities. For Aqara users who already own an Aqara Zigbee hub, deploying a Hub M3 further strengthens the robustness of their smart home networks. Moreover, it enables more local automations between Aqara devices. Once added to the network, the M3 takes a lead over other Aqara Zigbee hubs and Wi-Fi devices, and allows automation between these devices to execute on the Edge instead of over the cloud, ensures continued functionality during internet or cloud service disruptions2. The Hub M3 also allows select Aqara Zigbee devices with Repeater functionality to act as a proxy hub and execute automations in the absence of M3. Upcoming Aqara Thread devices with Mesh Extender functionality are expected to support device binding via the M3.
As the latest evolution in Aqara’s lineup of smart home control centers, the M3 supports multiple protocols including Thread, Zigbee, Wi-Fi, Bluetooth and infrared (IR), making it a comprehensive hub for smart home management. It connects and manages the lineup of classic Aqara Zigbee devices, serving as a Matter bridge3. Thanks to the 360° IR blaster, the new hub optimizes control of IR-enabled devices by syncing their status directly with Aqara Home whenever an IR remote is utilized. Moreover, the M3 integrates the latest Aqara Thread devices as well as select Matter-compatible devices from third-party brands to Aqara Home4. This means that users can connect and manage devices from different brands and ecosystems within the Aqara Home app to ensure maximum flexibility and compatibility.
Other enhancements of the Hub M3 include:
- Matter bridge for infrared AC units: It can integrate an infrared-compatible air conditioning unit or air-to-air heat pump to Matter, allowing for AC control and automation via Matter-enabled platforms5.
- Seamless group migration: Users can easily migrate bridged device from older Aqara hubs to the M32, ensuring continuity of Aqara Home settings and automations without the need to reconfigure each device.
- Enhanced internet connectivity: The M3 features dual-band Wi-Fi (2.4GHz/5GHz) with WPA3 security as well as a PoE-enabled port, offering enhanced stability and flexibility.
- Powerful speaker: The 95dB speaker built-in can be used for home security alerts and custom announcements.
The Hub M3 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide.
For more information on the M3, please visit our website.
1. Some Aqara Home automation may require Internet and cloud service to function, for example, automations involve push notifications and location services (e.g., geofencing, local weather, sunrise/sunset).
2. Edge automation and group migration are not supported by the original Aqara Hub and Camera Hub G2H.
3. Not all Aqara Zigbee devices can be bridged to Matter.
4. Third-party Matter device support is limited to select brands and device types by the time of M3 launch.
5. The functionality of infrared AC units may vary depending on each particular Matter-enabled platform. Each M3 hub can bridge one infrared AC unit to Matter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508489885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom